Personalized Gene Editing to Treat an Inborn Error of Metabolism | NEJM
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
Related Articles
Interview with Alice Chen on responding to the U.S. administration’s threats to health and physicians’ values and maintaining hope in difficult times. | NEJM
Audio Interview from the New England Journal of Medicine — Interview with Alice Chen on responding to the U.S. administration’s threats to health and physicians’…
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease | NEJM
Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated…
Personalized Gene Editing to Treat an Inborn Error of Metabolism | NEJM
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
Personalized Gene Editing to Treat an Inborn Error of Metabolism | NEJM
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis | NEJM
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclero…
Archives of Disease in Childhood: 110 (6)
(16 May, 2025) Free Nick Brown (12 March, 2025) Alison Clayton (19 January, 2025) Robert Wheeler (15 January, 2025) Free Charles Moorcroft, Abigail Whitehouse, Jonathan…
Interferon Lowers Myelofibrosis Risk in Young Patients With Polycythemia Vera, Essential Thrombocytopenia
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
Skin in the Game: Tackling Atopic Dermatitis with Topical Treatment
Omar Noor, MD, FAAD and Randy Alevi, DO, discuss the identification and management of atopic dermatitis, with a focus on topical treatment options. They discuss the…
Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | NEJM
Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival…
Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | NEJM
Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival…
